The spatial folding of chromosomes inside the nucleus has regulatory effects on gene expression, yet the impact of genome reshuffling on this organization remains unclear. Here, we take advantage of chromosome conformation capture in combination with single-nucleotide polymorphism (SNP) genotyping and analysis of crossover events to study how the higher-order chromatin organization and recombination landscapes are affected by chromosomal fusions in the mammalian germ line.

 

We demonstrate that chromosomal fusions alter the nuclear architecture during meiosis, including an increased rate of heterologous interactions in primary spermatocytes, and alterations in both chromosome synapsis and axis length.

 

These disturbances in topology were associated with changes in genomic landscapes of recombination, resulting in detectable genomic footprints. Overall, we show that chromosomal fusions impact the dynamic genome topology of germ cells in two ways: (i) altering chromosomal nuclear occupancy and synapsis, and (ii) reshaping landscapes of recombination.

 

Profiles of immune cell infiltration and immune-related genes in the tumor microenvironment of HNSCC with or without HPV infection

Head and neck squamous cell carcinoma (HNSCC) are the sixth most common cancer type in the world. Human papillomavirus (HPV) infection is an emerging risk factor for HNSCC. Immune infiltration of HNSCC is linked to therapeutic results. This article aimed to decide whether variations in HPV status affect immune infiltration, molecular mechanism, and how these results vary in HNSCC patients.

 

We investigated the tumor-infiltrating immune cells (TIICs) and immune-related gene differences between HPV (+) and HPV (-) HNSCC. The gene expression quantification data of HNSCC and their clinical information were download from the TCGA database. Immune-related genes have been linked to the ImmPort platform.

 

After analyzed of 22 TIICs in the HNSCC tumor environment by CIBERSORT and further assessment, lower memory B cell and higher T cell regulatory were connected with better HPV (-) HNSCC outcome, higher activated memory CD4 T cell, higher T cell regulatory, and lower activated NK cell were linked with better HPV (+) result.

 

We finally got five forms of immune genes (CAMP, EDNRB, NTS, CXCL9, LHB) associated with HNSCC progression. Higher expressions of CAMP, EDNRB, and NTS were associated with increased overall survival in HPV (-) patients. Higher expression of CXCL9 and lower expression of LHB contributed to increased overall survival of HPV (+) patients.

 

There tend to be discrepancies in the cell structure of TIICs and immune-related genes in HPV (-) and HPV (+) HNSCC. These variances are typically too crucial for the therapeutic outcome of the patient and the development of the tumor. In specific, our sample established these candidate immune cells and immune-related genes as candidate reservoirs for further researches.

Multi-ancestry genome-wide association study identifies 27 loci associated with measures of hemolysis following blood storage

The evolutionary pressure of endemic malaria and other erythrocytic pathogens has shaped variation in genes encoding erythrocyte structural and functional proteins, influencing responses to hemolytic stress during transfusion and disease.

 

We sought to identify such genetic variants in blood donors by conducting a genome-wide association study (GWAS) of 12,353 volunteer donors, including 1,483 African Americans, 1,477 Asians, and 960 Hispanics, whose stored erythrocytes were characterized by quantitative assays of in vitro osmotic, oxidative, and cold-storage hemolysis.

GWAS revealed 27 significant loci (p<5×10-8), many in candidate genes known to modulate erythrocyte structure, metabolism, and ion channels, including SPTA1, ALDH2, ANK1, HK1, MAPKAPK5, AQP1, PIEZO1, and SLC4A1/Band 3. GWAS of oxidative hemolysis identified variants in antioxidant enzymes including GLRX, GPX4, G6PD, and a novel golgi-transport protein SEC14L4.

 

Genome wide significant loci were also tested for association with the severity of steady state (baseline) in vivo hemolytic anemia in patients with sickle cell disease, with confirmation of identified SNPs in HBA2, G6PD, PIEZO1, AQP1 and SEC14L4. Many of the identified variants, such as those in G6PD, have previously been shown to impair erythrocyte recovery after transfusion, associate with anemia, or cause rare Mendelian human hemolytic diseases.

Candidate SNPs in these genes, especially in polygenic combinations, may affect RBC recovery after transfusion and modulate disease severity in hemolytic diseases, such as sickle cell disease and malaria.

Incorporating Genomic and Genetic Testing into the Treatment of Metastatic Luminal Breast Cancer

Background: Treatment of patients with luminal metastatic breast cancer (MBC) has become even more complex over the last few years as molecular profiling has begun to alter disease management. It is well accepted that MBC is not curable but is treatable. Today we are able to prolong progression-free survival and partly overall survival with targeted and more individual treatment strategies adjusted according to the molecular subtype.

Summary: Genetic and genomic testing has become therapeutically relevant in luminal MBC and is therefore an integral component within the treatment spectrum. By now, germline testing of BRCABRCAPIK3CA mutations are inevitable elements in disease management and the current state of the art in luminal MBC patients.

Furthermore, testing of ESR1 resistance mutation, ERBB2 mutation, microsatellite instability, and neurotrophic tyrosine receptor kinase (NTRK) gene fusion (mainly in secretory breast cancer) has recently gained increasing attention. However, based on the expanding role of personalized medicine, clinicians are now faced with substantial new challenges and possibly unsuspected possibilities. The following review summarizes current developments in genetic and genomic testing in luminal MBC.

Key messages: In luminal MBC genomics have become an integral component within the spectrum of oncological treatment establishing novel therapeutic facilities. Further developments in treatment personalization adjusted according to the molecular subtype should become increasingly important in order to enhance the progress of de-escalation of chemotherapy in luminal MBC. However, based on the expanding role of personalized medicine, clinicians are now faced with substantial new challenges and possibly unsuspected possibilities.

 

HIV-1 p24 ELISA Kit
Z7040001	Biochain	1 kit	EUR 812
Description: Premade ready to use kits will always come in handy. Get your experiment done right form the first try by using a validated kit with perfectly balanced reagents proportions and compatibility and by following a clear protocol.

HIV-1 p24
E5-00024	EnoGene	1mg	EUR 960

HIV-1 p24
E62H002	EnoGene	100ug	EUR 382

HIV Type 1 p24 Antigen ELISA (96 Determinations)
0801111	Zeptometrix	96T	EUR 548.16
Description: Please contact Gentaur in order to receive the datasheet of the product.

HIV Type 1 p24 Antigen ELISA 2.0 (96 Determinations)
0801002	Zeptometrix	96T	EUR 548.16
Description: Please contact Gentaur in order to receive the datasheet of the product.

HIV type 1 P24
DAG1520	Creative Diagnostics	100 µg	EUR 810

HIV-1 p24 Antibody
20-abx137062	Abbexa	EUR 356.00 EUR 523.00	0.5 mg 1 mg

Recombinant HIV-1 p24
7-07603	CHI Scientific	100µg	Ask for price

Recombinant HIV-1 p24
7-07604	CHI Scientific	500µg	Ask for price

Recombinant HIV-1 p24
7-07605	CHI Scientific	1000µg	Ask for price

HIV 1 p24 Protein
abx060589-1mg	Abbexa	1 mg	EUR 1288

HIV-1 p24 Protein
abx061424-05mg	Abbexa	0.5 mg	EUR 739

HIV-1, p24 Protein
abx069857-1mg	Abbexa	1 mg	EUR 1574

HIV-1 p24 Antibody
abx021869-1mg	Abbexa	1 mg	EUR 662

HIV-1 p24 Antibody
abx021870-1mg	Abbexa	1 mg	EUR 634

HIV-1 p24 Antibody
abx021871-1mg	Abbexa	1 mg	EUR 662

HIV-1 p24 Antibody
abx021872-1mg	Abbexa	1 mg	EUR 662

HIV-1 p24 Antibody
abx021873-1mg	Abbexa	1 mg	EUR 662

HIV-1 p24 Antibody
abx021882-1mg	Abbexa	1 mg	EUR 982

HIV-1 p24 Antibody
abx021883-1mg	Abbexa	1 mg	EUR 1017

HIV-1 p24 Antibody
abx021886-1mg	Abbexa	1 mg	EUR 1017

HIV-1 p24 Antibody
abx021887-1mg	Abbexa	1 mg	EUR 1017

HIV-1 p24 Antibody
abx021888-1mg	Abbexa	1 mg	EUR 1017

HIV-1 p24 Antibody
abx023027-1ml	Abbexa	1 ml	EUR 578

HIV-1 p24 Antibody
abx023925-1mg	Abbexa	1 mg	EUR 690

HIV-1 p24 Antibody
abx023926-1mg	Abbexa	1 mg	EUR 690

HIV-1 p24 Protein
abx169032-1mg	Abbexa	1 mg	EUR 551

HIV-1 p24 Protein
20-abx261886	Abbexa	EUR 4490.00 EUR 328.00 EUR 230.00	1 mg 20 ug 5 ug

HIV-1 Gag p24
05-005	Sceti	50 ug	EUR 362
Description: The HIV-1 Gag p24 is available in Europe and for worldwide shipping via Gentaur.

HIV-1 Gag p24
05-006	Sceti	250 ug	EUR 962
Description: The HIV-1 Gag p24 is available in Europe and for worldwide shipping via Gentaur.

HIV-1 p24 Antibody
7313-002mg	ProSci	0.02 mg	EUR 171.82
Description: HIV-1 p24 Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix. The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein. The p24 is the major capsid protein of the virus and has been used in clinical trials as one of the components of the HIV-1 vaccine because of the high degree of sequence conservation between different strains.

HIV-1 p24 Antibody
7313-01mg	ProSci	0.1 mg	EUR 436.42
Description: HIV-1 p24 Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix. The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein. The p24 is the major capsid protein of the virus and has been used in clinical trials as one of the components of the HIV-1 vaccine because of the high degree of sequence conservation between different strains.

p24-HIV(p24/661) Antibody
BNCA0661-250	Biotium	250uL	EUR 383
Description: Primary antibody against p24-HIV(p24/661), APC conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody
BNCAP0661-100	Biotium	100uL	EUR 199
Description: Primary antibody against p24-HIV(p24/661), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody
BNCAP0661-500	Biotium	500uL	EUR 544
Description: Primary antibody against p24-HIV(p24/661), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody
BNC810661-100	Biotium	100uL	EUR 199
Description: Primary antibody against p24-HIV(p24/661), CF680R conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody
BNC810661-500	Biotium	500uL	EUR 544
Description: Primary antibody against p24-HIV(p24/661), CF680R conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody
BNC880661-100	Biotium	100uL	EUR 199
Description: Primary antibody against p24-HIV(p24/661), CF488A conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody
BNC880661-500	Biotium	500uL	EUR 544
Description: Primary antibody against p24-HIV(p24/661), CF488A conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody
BNCB0661-100	Biotium	100uL	EUR 199
Description: Primary antibody against p24-HIV(p24/661), Biotin conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody
BNCB0661-500	Biotium	500uL	EUR 544
Description: Primary antibody against p24-HIV(p24/661), Biotin conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody
BNC550661-100	Biotium	100uL	EUR 199
Description: Primary antibody against p24-HIV(p24/661), CF555 conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody
BNC550661-500	Biotium	500uL	EUR 544
Description: Primary antibody against p24-HIV(p24/661), CF555 conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody
BNC430661-100	Biotium	100uL	EUR 199
Description: Primary antibody against p24-HIV(p24/661), CF543 conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody
BNC430661-500	Biotium	500uL	EUR 544
Description: Primary antibody against p24-HIV(p24/661), CF543 conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody
BNC470661-100	Biotium	100uL	EUR 199
Description: Primary antibody against p24-HIV(p24/661), CF647 conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody
BNC470661-500	Biotium	500uL	EUR 544
Description: Primary antibody against p24-HIV(p24/661), CF647 conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody
BNC940661-100	Biotium	100uL	EUR 199
Description: Primary antibody against p24-HIV(p24/661), CF594 conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody
BNC940661-500	Biotium	500uL	EUR 544
Description: Primary antibody against p24-HIV(p24/661), CF594 conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody
BNCP0661-250	Biotium	250uL	EUR 383
Description: Primary antibody against p24-HIV(p24/661), PerCP conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody
BNC040661-100	Biotium	100uL	EUR 199
Description: Primary antibody against p24-HIV(p24/661), CF405S conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody
BNC040661-500	Biotium	500uL	EUR 544
Description: Primary antibody against p24-HIV(p24/661), CF405S conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody
BNC050661-100	Biotium	100uL	EUR 199
Description: Primary antibody against p24-HIV(p24/661), CF405M conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody
BNC050661-500	Biotium	500uL	EUR 544
Description: Primary antibody against p24-HIV(p24/661), CF405M conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody
BNCR0661-250	Biotium	250uL	EUR 383
Description: Primary antibody against p24-HIV(p24/661), RPE conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody
BNUB0661-100	Biotium	100uL	EUR 209
Description: Primary antibody against p24-HIV(p24/661), Concentration: 0.2mg/mL

p24-HIV(p24/661) Antibody
BNUB0661-500	Biotium	500uL	EUR 458
Description: Primary antibody against p24-HIV(p24/661), Concentration: 0.2mg/mL

p24-HIV(p24/661) Antibody
BNC680661-100	Biotium	100uL	EUR 199
Description: Primary antibody against p24-HIV(p24/661), CF568 conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody
BNC680661-500	Biotium	500uL	EUR 544
Description: Primary antibody against p24-HIV(p24/661), CF568 conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody
BNC700661-100	Biotium	100uL	EUR 199
Description: Primary antibody against p24-HIV(p24/661), CF770 conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody
BNC700661-500	Biotium	500uL	EUR 544
Description: Primary antibody against p24-HIV(p24/661), CF770 conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody
BNC400661-100	Biotium	100uL	EUR 199
Description: Primary antibody against p24-HIV(p24/661), CF640R conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody
BNC400661-500	Biotium	500uL	EUR 544
Description: Primary antibody against p24-HIV(p24/661), CF640R conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody
BNC610661-100	Biotium	100uL	EUR 199
Description: Primary antibody against p24-HIV(p24/661), CF660R conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody
BNC610661-500	Biotium	500uL	EUR 544
Description: Primary antibody against p24-HIV(p24/661), CF660R conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody
BNC800661-100	Biotium	100uL	EUR 199
Description: Primary antibody against p24-HIV(p24/661), CF680 conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody
BNC800661-500	Biotium	500uL	EUR 544
Description: Primary antibody against p24-HIV(p24/661), CF680 conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody
BNCH0661-100	Biotium	100uL	EUR 199
Description: Primary antibody against p24-HIV(p24/661), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody
BNCH0661-500	Biotium	500uL	EUR 544
Description: Primary antibody against p24-HIV(p24/661), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody
BNUM0661-50	Biotium	50uL	EUR 395
Description: Primary antibody against p24-HIV(p24/661), 1mg/mL

HIV p24 Antibody
abx021867-1mg	Abbexa	1 mg	EUR 1344

HIV p24 Antibody
abx021868-1mg	Abbexa	1 mg	EUR 1344

Human(HIV-P24)
QY-E05679	Qayee Biotechnology	96T	EUR 361

HIV Type 1 p24 Antigen ELISA (5 X 96 Determinations)
0801200	Zeptometrix	5 X 96T	EUR 2119.6
Description: Please contact Gentaur in order to receive the datasheet of the product.

HIV type 1 P24 [GST]
DAG1516	Creative Diagnostics	100 µg	EUR 645

HIV type 1 P24 [His]
DAG1518	Creative Diagnostics	100 µg	EUR 645

HIV type 1 P24 [Biotin]
DAG1519	Creative Diagnostics	100 µg	EUR 810

HIV type 1 P24 [His]
DAG1799	Creative Diagnostics	50 ug	EUR 1681

HIV type 1 P24 [His]
DAG2375	Creative Diagnostics	100 µg	EUR 724

HIV type 1 P24 [His]
DAG2377	Creative Diagnostics	100 µg	EUR 724

HIV type 1 p24 [FITC]
DAGH004	Creative Diagnostics	50 Tests	EUR 927

HIV-1 p24, His tag
E410A26-20	EnoGene	20μg	EUR 434

Recombinant HIV-1 p24 Core
7-07597	CHI Scientific	100µg	Ask for price

Recombinant HIV-1 p24 Core
7-07598	CHI Scientific	500µg	Ask for price

Recombinant HIV-1 p24 Core
7-07599	CHI Scientific	1000µg	Ask for price

Recombinant HIV-1 p24 , 24kDa
7-07621	CHI Scientific	2µg	Ask for price

Recombinant HIV-1 p24 , 24kDa
7-07622	CHI Scientific	10µg	Ask for price

Recombinant HIV-1 p24 , 24kDa
7-07623	CHI Scientific	100µg	Ask for price

HIV 1 / 2 p24 Antibody
abx021866-1mg	Abbexa	1 mg	EUR 1010

HIV-1 p24 Antibody (FITC)
abx021884-100ug	Abbexa	100 ug	EUR 739